Matthias Hoch
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
Journal: Leukemia
Published: March 05, 2026
Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.
Journal: Clinical pharmacokinetics
Published: November 17, 2025
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase.
Journal: Clinical pharmacokinetics
Published: August 03, 2025
Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib.
Journal: Pharmaceutics
Published: August 01, 2025
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: June 26, 2025
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.
Journal: Cancer chemotherapy and pharmacology
Published: June 18, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.
Journal: Leukemia
Published: February 21, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
Journal: Leukemia
Published: February 14, 2025
Clinical Pharmacology of Asciminib: A Review.
Journal: Clinical pharmacokinetics
Published: September 06, 2024
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
Journal: Cancer chemotherapy and pharmacology
Published: August 21, 2024
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.
Journal: Clinical pharmacokinetics
Published: August 09, 2024
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model.
Journal: British journal of clinical pharmacology
Published: July 30, 2024
Last Updated: 09/26/2026